Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BNT314

Bispecific antibody · Immune activation, directed at EpCAM and 4-1BB (CD137) (TNFRSF9) · developed by BioNTech

Phase 1 Most advanced trial
BNTX Developer
1 Registered trials

What is BNT314?

BNT314 is a bispecific antibody that binds EpCAM on tumor cells and the costimulatory receptor 4-1BB on leukocytes, including activated T lymphocytes. By crosslinking these cells, it activates 4-1BB signaling locally in the tumor microenvironment to co-stimulate cytotoxic T cells. It is studied in advanced malignant solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
EpCAM, 4-1BB (CD137) (TNFRSF9)
Mechanism
Immune activation, directed at EpCAM and 4-1BB (CD137) (TNFRSF9)
Pathways
T-cell costimulation, T-cell proliferation and survival, cytolytic T-cell activity
Therapy area
Oncology
Developer
BioNTech SE (BNTX)
Also in trials of
GMAB
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06150183 Phase 1 Advanced Malignant Solid Tumor Active not recruiting BNTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Malignant Solid Tumor

Other drugs acting on EPCAM / TNFRSF9

More from BioNTech

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BNTX page.

Follow BNTX, the company behind BNT314

See BNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BNTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.